India’s Generics-Big Pharma Battle Drops Drug Prices, Raises Legal Debate 20/05/2012 by Patralekha Chatterjee for Intellectual Property Watch 11 Comments The escalating battle between Big Pharma and India’s generic drug manufacturers is pushing down medicine prices in one of the world’s fastest growing pharmaceutical markets.
Singapore Builds Patent Capacity Ahead Of New System 17/05/2012 by Maricel Estavillo for Intellectual Property Watch 2 Comments The tiny island state of Singapore has begun to ramp up its capacity for patent search and examination ahead of a bold move to adopt a new patent system, one of the proposed major amendments to its Patents Act. The Southeast Asian economic high-flyer is pressing for changes to its laws to position itself as an Asian hub for intellectual property.
Amid “Korean Wave,” South Korea Opens IP Office In The Philippines 14/05/2012 by Maricel Estavillo for Intellectual Property Watch 1 Comment The Republic of Korea has opened its fourth satellite copyright office, in the Philippines, in a bid to protect its copyrighted works amid the popularity of Korean entertainment in this Southeast Asian nation.
Book Offers Timely Insights On IP, Drugs And Public Health In Developing Countries 25/04/2012 by Intellectual Property Watch Leave a Comment A recent book comes in time for the international policy debates coming to a head over access to medicines, intellectual property rights and public health in developing countries.
Trade And Development With A Dash Of IP: Conference To Set Course For UNCTAD 11/04/2012 by Catherine Saez, Intellectual Property Watch Leave a Comment The quadrennial conference of the United Nations Conference on Trade and Development (UNCTAD) sets the course of the UN body work for the next four years. The mandate of the conference has evolved since its creation to become mainly a provider of research, policy analysis and technical assistance to developing countries. This time around, the conference will serve as a wide-ranging forum for trade and development issues, and intellectual property issues will haunt discussions in several areas.
Novartis India Challenge Postponed To July 28/03/2012 by Intellectual Property Watch 2 Comments The Indian Supreme Court today postponed hearing the high-profile case involving Swiss pharmaceutical producer Novartis’ challenge of India’s patent law until July, according to sources.
Singapore Seeks To Liberalise Patent Law In Bid To Become IP Hub 16/03/2012 by Maricel Estavillo for Intellectual Property Watch 1 Comment South-east Asia’s economic juggernaut Singapore will hold a public consultation on a proposal to liberalise its patent law in a bid to cement its position as the intellectual property (IP) hub in the region.
Intérêt de l’entreprise et choix stratégiques : les licences concédées par Gilead au Medicines Patent Pool 14/03/2012 by Intellectual Property Watch Leave a Comment Bien que Gilead ait apporté des améliorations considérables à ses précédentes licences volontaires portant sur des médicaments antirétroviraux essentiels, les licences que l’entreprise a concédées au Medicines Patent Pool, fondation créée par UNITAID, comportent des restrictions regrettables qui fragilisent leur impact sur l’accès à des antirétroviraux génériques de qualité garantie plus abordables dans les pays en développement.
India Grants First Compulsory Licence, For Bayer Cancer Drug 12/03/2012 by Maricel Estavillo for Intellectual Property Watch 8 Comments In a move welcomed by many in the international community, India has granted an application, its first, from a homegrown generic drug maker to manufacture and sell a patented cancer drug under a compulsory licence.
Novartis Before India’s Supreme Court: What’s Really At Stake? 02/03/2012 by Rachel Marusak Hermann, Intellectual Property Watch 3 Comments As the Novartis Glivec patent case in India reaches the final phase of a long-running legal battle, there’s one point on which both the Swiss pharmaceutical company and its critics agree: the significance of this case goes far beyond the protection of a single medication.